Results
|
|
1.
|
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors:
Year: 2013
Citation: - Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM
|
|
|
2.
|
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. MedStar authors:
Year: 2013
Citation: - Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Brewster M, Cortes J, Garg A, Grincuka E, Hauschild M, Kudaba I, Lum BL, Marier JF, Masuda N, McNally V, Nijem I, Patel T, Ross G, Swain SM, Trinh MM, Visich J
|
|
|
3.
|
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors:
Year: 2017
Citation: - Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N
|
